Daily Updates on Generic Entry, Litigation, Biosimilars, and more …
Want insights into the biggest revenue-changing events?
Billions of dollars in sales can evaporate overnight as drug patents expire and competitors enter the market.
By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
Pediatric Kidney Transplant Without Calcineurin Inhibitors
Completed
National Institute of Allergy and Infectious Diseases (NIAID)
N/A
2001-02-01
The purpose of this study is to see the effect of using drugs other than calcineurin
inhibitors to improve the rate of kidney transplant failure.
Kidney transplantation can help children with end-stage kidney disease. However, it has been
difficult to find treatment for donor graft rejection that does not have a lot of side
effects. Researchers hope to find treatments (immunosuppressants) with fewer side effects.
One approach is to avoid using calcineurin inhibitors and to try a new drug known as
sirolimus instead. Another is to use steroids less often. This study will test whether using
sirolimus, fewer steroid treatments, MMF, and certain antibodies will improve long-term
graft survival in children receiving kidney transplants from living donors.
Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)
Completed
Laura Schanberg
Phase 3
2003-09-01
The purpose of this study is:
1. To assess the efficacy of a lipid-lowering agent (atorvastatin) on the development of
atherosclerosis that predisposes children with SLE to cardiovascular events in
adulthood.
2. To assess the safety of intermediate-term (36 months) treatment of children and young
adults with atorvastatin.
3. To further characterize the course of SLE in children and young adults, by establishing
a cohort of pediatric SLE patients to be followed prospectively.
4. To establish a mechanism for conducting clinical trials in rare pediatric rheumatic
diseases using the Children's Arthritis and Rheumatology Research Alliance (CARRA).
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
